1Cohen HT, McGovern FJ. Renal-cell carcinoma [ J ]. N Engl J Med ,2005,353 ( 23 ) :2477 - 2490.
2Garcia JA,Rini BI. Recent progress in the management of advanced renal cell carcinoma [J]. CA Cancer J Clin, 2007,57(2) :112 - 125.
3Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy [ J ]. J Clin Oncol, 1995,13 ( 3 ) : 688 - 696.
4Sabatino M, Kim SS, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinieal response to high-dose interleukin-2 therapy [ J ]. J Clin Oncol,2009,27 ( 16 ) :2645 - 2652.
5Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer [J]. J Clin Oncol,2007,25(22) :3288 -3295.
6Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Meal,2007,356(2) :115 - 124.
7Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [ J]. Cancer Res ,2004,64(19) :7099 - 7109.
8Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [ J ]. N Engl J Meal,2007,356 ( 2 ) : 125 - 134.
9Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial [ J ]. J Natl Cancer Inst,2008,100 (20) : 1454 - 1463.
10Motzer R J, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma [ J ]. J Clin Oncol, 2009,27 ( 22 ) : 3584 - 3590.
2Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA CancerJ Clin, 2011, 61(2): 69-90.
3Uchida K, Miyao N, Masumori N, et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy[J]. Int J Urol, 2002, 9(1): 19-23.
4GarciaJ A, Rini B I. Recent progress in the management of advanced renal cell carcinoma[J].CA CancerJ Clin, 2007, 57(2): 112-125.
5Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)[J].J Cancer Res Clin Oncol,2011,137(2):305-310.
6Li H, Wang C, Yu j, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J]. Cytotherapy, 2009, 11(8): 1076-1083.
7Ren X, YuJ, Liu H, et al. Thl bias in PBMC induced by multicy- cles of auto-CIKs infusion in malignant solid tumor patients[J]. Cancer Biother Radiopharm, 2006, 21(1):22-33.
8Motzer R J, Bacik J, Murphy B A, et al. Interferon-alfa as a com- parative treatment for chnical trials of new therapies against ad- vanced renal cell carcinoma[J].J Clin Oncol, 2002, 20(1): 289-296.
9Sabatino M, Kim-Schulze S, Panelli M C, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to I high-dose interleukin-2 therapy[J]. J Clin Oncol, 2009, 27(16): 2645-2652.
10Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus in- terferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial[J]. Lancet, 2007, 370(9605): 2103-2111.
